B

Bangkok Dusit Medical Services PCL
SET:BDMS

Watchlist Manager
Bangkok Dusit Medical Services PCL
SET:BDMS
Watchlist
Price: 18.7 THB 0.54% Market Closed
Market Cap: ฿297.2B

EV/EBIT

15.1
Current
32%
Cheaper
vs 3-y median of 22.1

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
15.1
=
Enterprise Value
฿312B
/
EBIT
฿20.2B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
15.1
=
Enterprise Value
฿312B
/
EBIT
฿20.2B

Valuation Scenarios

Bangkok Dusit Medical Services PCL is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (22.1), the stock would be worth ฿27.42 (47% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-23%
Maximum Upside
+63%
Average Upside
17%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 15.1 ฿18.7
0%
3-Year Average 22.1 ฿27.42
+47%
5-Year Average 24.6 ฿30.5
+63%
Industry Average 12.2 ฿15.1
-19%
Country Average 11.7 ฿14.47
-23%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
฿312B
/
Jan 2026
฿20.2B
=
15.1
Current
฿312B
/
Dec 2026
฿22.4B
=
13.9
Forward
฿312B
/
Dec 2027
฿22.1B
=
14.1
Forward
฿312B
/
Dec 2028
฿24.1B
=
13
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close

Market Distribution

In line with most companies in Thailand
Percentile
68th
Based on 357 companies
68th percentile
15.1
Low
0.4 — 8.7
Typical Range
8.7 — 15.7
High
15.7 —
Distribution Statistics
Thailand
Min 0.4
30th Percentile 8.7
Median 11.7
70th Percentile 15.7
Max 2 524.8

Bangkok Dusit Medical Services PCL
Glance View

Market Cap
297.2B THB
Industry
Health Care

Bangkok Dusit Medical Services PCL (BDMS) stands as a beacon of healthcare excellence in Thailand, playing a crucial role in providing comprehensive medical care since its inception. Founded in 1969, BDMS has steadily expanded its footprint to become one of the largest private hospital operators in the region. Anchored in Bangkok, the heart of Thailand's urban landscape, the company operates a network of hospitals across Southeast Asia. With a portfolio that includes several specialized centers and well-established hospital brands like Bangkok Hospital, Samitivej, and BNH Hospital, BDMS caters to a diverse patient base ranging from local and international patients to expatriates. The company's business model revolves around leveraging a mix of advanced medical technology and a highly skilled medical workforce to offer a wide range of healthcare services, from routine check-ups and wellness programs to complex surgical procedures. Financially, BDMS derives its revenue through various healthcare services, taking advantage of Thailand's growing reputation as a premier destination for medical tourism. The company earns from patient consultations, diagnostic services, surgical procedures, and inpatient care. A signature of BDMS's approach has been its investment in cutting-edge medical equipment and continuous medical education, which keeps its service quality at par with international standards. Additionally, the group's proactive expansion strategy, incorporating acquisitions and the development of specialty centers, has secured its leadership status in the healthcare sector. This well-orchestrated blend of strategic expansion and diversified service offerings ensures a steady stream of revenue and bolsters BDMS's position as a cornerstone of private healthcare in the region.

BDMS Intrinsic Value
LOCKED
Unlock
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett